细胞治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2031 年的预测

  • Report Code : TIPRE00024331
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 138
Buy Now

【研究报告】2022年T细胞治疗市场规模为27.54亿美元,预计到2030年将达到90.3501亿美元,预计2022-2030年复合年增长率为16.0%。

市场洞察和分析师观点:

最有前途的癌症治疗方法之一是嵌合抗原受体 (CAR) T 细胞疗法,每年都有越来越多的临床前和正在进行临床研究以扩大其应用。 CAR T 细胞疗法也引起了肿瘤学家和学者的兴趣。免疫检查点抑制剂比 CAR T 细胞疗法更常见、使用更广泛,尽管 CAR T 细胞疗法表现出同样的能力,可以摧毁极其晚期的白血病和淋巴瘤,并使疾病远离许多年。预计医院将广泛采用CAR-T细胞疗法;然而,为了提供这种治疗,制造和医疗领域必须建立一个生态系统来收集原材料、加工产品、分配产品和监测患者。由于全球癌症负担日益加重以及 T 细胞治疗批准数量不断增加,对 T 细胞治疗的需求不断增长。

在 T 细胞治疗市场运营的公司专注于合作等战略发展、协议和投资,以改善其销售、扩大其地理覆盖范围并增强其满足比现有客户群更大的客户群的能力。例如,2023年8月,安斯泰来投资5000万美元用于Poseida的CAR T细胞疗法。作为协议的一部分,安斯泰来将就 P-MUC1C-ALLO1 在实体瘤中的许可进行排他性谈判和优先拒绝权。

增长动力和挑战:

据世界卫生组织称据世界卫生组织 (WHO) 统计,2020 年,癌症是全球主要死因,约 1000 万人因癌症死亡。据国际癌症研究机构称,到2040年,全球癌症负担将新增3020万例。嵌合抗原受体 (CAR) T 细胞疗法有可能治疗一种利用免疫系统对抗癌症的新型癌症治疗方法。 CAR T细胞是创新药物,基于其成功的临床试验获得FDA批准,扭转了治疗血液恶性肿瘤的局面,例如弥漫性大B细胞淋巴瘤(DLBCL)和B细胞急性淋巴细胞白血病(B-ALL)结果。根据白血病和淋巴瘤协会的数据,在美国每 3 分钟就有大约 1 个人被诊断患有白血病、淋巴瘤或骨髓瘤。到2023年,预计美国将有近18万人被诊断出淋巴瘤和白血病。

基于T细胞的技术因其较高的成功率而经常用于癌症免疫治疗。 2021年,Labiotech.eu(欧洲生物科技行业领先在线媒体)表示,全球正在开展超过500项用于癌症治疗的CAR T细胞临床试验。大多数是在东亚、美国和欧洲进行的。因此,日益增加的癌症负担正在推动T细胞疗法市场的增长。

由于CAR T细胞疗法很复杂,因此会产生一些高风险的副作用。 CAR T 细胞疗法引起的最常见和最严重的副作用之一是细胞因子释放综合征(CRS)。 CAR T 细胞疗法的其他副作用是神经系统影响,包括严重混乱、癫痫样活动和言语障碍。神经毒性是大多数抗 CD19 CAR T 细胞治疗患者的副作用。 ICANS 是 CAR T 细胞治疗的一种常见且具有挑战性的不良反应,25-44% 的血液恶性肿瘤儿童会发生这种不良反应。 ICANS 通常在 CAR T 细胞输注后 7-10 天内发生,有时长达 3 周,并且可以在 CRS 后同时或不久发生。因此,治疗副作用的挑战限制了T细胞治疗市场的增长。

战略见解

报告细分和范围:

“全球 T 细胞治疗市场”根据模式、治疗类型和范围进行细分指示。根据形态,细分为研究和商业化。 2022年,商业化细分市场占据更大的市场份额。根据治疗类型,T 细胞市场分为 CAR T 细胞疗法和基于 T 细胞受体 (TCR) 的疗法。从适应症来看,T细胞治疗市场分为血液恶性肿瘤和实体瘤。 T细胞治疗市场根据地理位置分为北美(美国、加拿大和墨西哥)、欧洲(法国、德国、意大利、英国、西班牙和欧洲其他地区)、亚太地区(澳大利亚、中国、日本) 、韩国和亚太其他地区)、中东和非洲(沙特阿拉伯、以色列以及中东和非洲其他地区)以及南美洲和中美洲(巴西)。

细分分析:

按模式划分,T 细胞治疗市场分为研究型和商业化型。 2022年,商业化细分市场占据最大市场份额。此外,预计同一细分市场在预测期内增长最快。产品发布的增加以及人们对 T 细胞治疗癌症治疗益处的认识的提高,推动了商业化领域的增长。以下是一些商业化用于癌症治疗的产品。

2022年,FDA批准了Janssen Biotech, Inc.生产的CARVYKTI。它是一种用慢病毒改造的自体CAR-T细胞,可以攻击表达BCMA的肿瘤细胞,从而达到治疗癌症的目的。治疗某些类型的难治性多发性骨髓瘤。2022年1月,美国FDA批准了Immunocare生产的KIMMTRAK。它用于治疗不可切除或转移性葡萄膜黑色素瘤。T 细胞治疗市场,按模式 - 2022 年和 2030 年

根据治疗类型,T 细胞治疗市场分为 CAR T 细胞治疗和 T 细胞治疗受体(TCR)为基础。 2022年,CAR T细胞治疗领域占据更大的市场份额。此外,同一细分市场在预测期内将以显着的速度增长。在嵌合抗原受体(CAR)T细胞治疗技术中,从患者身上获得的T细胞经过人工生物工程改造,表达能够识别并附着在肿瘤细胞上的CAR。这些公司正在开展战略发展,例如合作、扩张、协议、伙伴关系以及 CAR T 细胞领域运营公司推出的新产品,从而推动 T 细胞治疗市场的增长。例如,2022年,FDA批准了Janssen Biotech, Inc.生产的CARVYKTI。CARVYKTI是一种名为CAR-T的疗法,即嵌合抗原受体T细胞。 CARVYKTI(ciltacabtagene autoleucel)是一种用于治疗患有骨髓癌(称为多发性骨髓瘤)的成年患者的治疗方法。 CARVYKTI 治疗经过四种或多种先前疗法的复发性或难治性多发性骨髓瘤成年患者,包括蛋白酶体抑制剂、免疫调节剂和抗 CD38 单克隆抗体。

T 细胞治疗市场根据适应症分为血液系统恶性肿瘤和实体瘤。 2022年,血液恶性肿瘤领域占据最大市场份额;预计同一细分市场在预测期内将以显着的速度增长。血液恶性肿瘤是影响人体血液、骨髓和淋巴结的癌症类型。白血病、淋巴瘤、骨髓瘤和骨髓瘤是一些血液系统恶性肿瘤。据白血病和淋巴瘤协会称,到 2023 年,预计美国约有 184,000 人被诊断患有白血病、淋巴瘤或骨髓瘤。据同一来源称,美国约有 1,629,000 人受到血液恶性肿瘤的影响或正在缓解。由于世界范围内血液恶性肿瘤患病率的增加,治疗方法发展迅速。

区域分析:

根据地理位置,T细胞治疗市场分为五个关键区域:北美、欧洲、亚太地区、南美洲和中美洲以及中东地区东非。对北美市场的分析主要集中在三个主要国家——美国、加拿大和墨西哥。到 2022 年,北美将占据最大的 T 细胞治疗市场份额。由于癌症和自身免疫性疾病等慢性疾病负担的增加、研发活动的增长以及强劲和强劲的发展,北美的 T 细胞治疗市场预计将增长。成熟的市场参与者。此外,随着 CAR T 细胞疗法临床研究的增加,预计北美市场在预测期内将会增长。

T 细胞疗法市场机会:

投资不断增长T 细胞治疗领域

在 T 细胞治疗市场运营的公司专注于战略发展,例如合作、扩张、协议和投资,以帮助他们提高销售额、扩大地理覆盖范围并增强能力以满足比现有客户群更大的需求。下面提到了 T 细胞治疗市场的一些值得注意的发展。

到 2023 年 5 月,Laurus Labs 在 ImmunoACT 中的股份在交易完成后将增至完全稀释后的 33.86%。该公司已于2021年11月收购了ImmunoACT 26.62%的股份。ImmunoACT拥有处于不同开发阶段的CAR T细胞治疗资产组合,用于治疗多种自身免疫性疾病和肿瘤学适应症。这项投资进一步加强了 Laurus Labs 对获取新型细胞和基因治疗技术的承诺,并提高了患者的负担能力。这项投资将进一步帮助ImmunoACT为更多治疗药物的制造做好准备。 2023年1月,加州再生医学研究所(CIRM)投资400万美元开发和测试CAR T细胞疗法,用于治疗各种B细胞恶性肿瘤2021 年 11 月,Autolus Therapeutics plc(一家开发下一代程序化 T 细胞疗法的临床阶段生物制药公司)与 Blackstone Life Sciences 签订了一项合作和融资协议,根据该协议,资金由 Blackstone 管理。 Blackstone 提供了高达 2.5 亿美元的股权和产品融资,用于支持 Autolus 开发其 CD19 CAR T 细胞研究性治疗产品 obecabtagene autoleucel (obe-cel) 以及肥胖症的下一代产品疗法。因此,这些投资在 T 细胞治疗市场创造了利润丰厚的机会。

竞争格局和主要公司:

全球 T 细胞治疗市场的一些知名参与者包括:Immunocore Holdings Plc、Legend Biotech Corp、Janssen Global Services LLC、吉利德科学公司 (Gilead Sciences Inc)、百时美施贵宝公司 (Bristol-Myers Squibb Co)、蓝鸟生物公司 (Bluebird Bio Inc)、诺华公司 (Novartis AG)、JW (Cayman) Therapeutics Co Ltd、Cartesian Therapeutics Inc 和信达生物制剂公司 (Innovent Biologics Inc.)。满足全球不断增长的消费者需求,并增加其专业产品组合的产品范围。这些公司在全球 T 细胞治疗市场上实施各种无机和有机开发。

2023年5月,传奇生物宣布,基于CARTITUDE-4研究数据(NCT04181827)向欧洲药品管理局(EMA)提交了CARVYKTI的II型变异申请。 ),该项目研究了既往接受过一到三种疗法的复发性和来那度胺难治性多发性骨髓瘤成年患者的治疗。 2023 年 3 月,JW Therapeutics 成立,这是一家专注于开发、制造和商业化细胞免疫疗法的独立创新生物技术公司产品,已启动Carteyva(relmacabtagene autoleucel注射液)用于高危大B细胞淋巴瘤患者一线治疗及首例患者输注的临床研究。2022年6月,美国食品药品监督管理局(FDA)批准Breyanzi (lisocabtagene maraleucel) 是一种 CD19 定向嵌合抗原受体 (CAR) T 细胞疗法,用于治疗成人大 B 细胞淋巴瘤 (LBCL) 患者,包括未另有说明的弥漫性大 B 细胞淋巴瘤 (DLBCL)。包括惰性淋巴瘤引起的 DLBCL)、高级别 B 细胞淋巴瘤、原发性纵隔大 B 细胞淋巴瘤和 3B 级滤泡性淋巴瘤。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is T cell therapy?

One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. Immune checkpoint inhibitors are more common and widely used than CAR T cell treatments, even though CAR T cell therapy demonstrated the same capacity to destroy extremely advanced leukemias and lymphomas and hold the disease away for many years.

What are the driving factors for the T cell therapy market across the globe?

The factors that are driving growth of the market are growing burden of cancer worldwide and an increasing number of T cell therapy approvals.

Who are the major players in the T cell therapy market?

The T cell therapy market majorly consists of the players such as Immunocore Holdings Plc, Legend Biotech Corp, Janssen Global Services LLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Bluebird Bio Inc, Novartis AG, JW (Cayman) Therapeutics Co Ltd, Cartesian Therapeutics Inc, and Innovent Biologics Inc. among others.

Which country is dominated the T cell therapy market?

US holds the largest market share in T cell therapy market. The growth of the market in the country is due to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players.

Which region is the fastest growing the T cell therapy market?

Asia Pacific is expected to be the fastest growing region in the T cell therapy market. The market in Asia Pacific is expected to witness significant growth as CAR T-cell therapy is efficient in treating cancer, elevating the market growth in the region. Many clinical trials for CAR T-cell therapy are ongoing in the region, offering new opportunities in APAC.

Which modality segment is dominating the T cell therapy market?

The T cell therapy market, based on modality, is bifurcated into research and commercialized. In 2022, the commercialized segment held the largest share of the market. Moreover, same segment is expected to grow at the fastest rate during the coming years.

The List of Companies - T Cell Therapy Market

  1. Immunocore Holdings Plc
  2. Legend Biotech Corp
  3. Janssen Global Services LLC
  4. Gilead Sciences Inc
  5. Bristol-Myers Squibb Co
  6. Bluebird Bio Inc
  7. Novartis AG
  8. JW (Cayman) Therapeutics Co Ltd
  9. Cartesian Therapeutics Inc
  10. Innovent Biologics Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports